RFRomain H. Fontaine

Romain H. Fontaine

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Romain H. Fontaine has a total of 121 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Local Inhibition of MEK/Akt Prevents Cellular Growth in Human Congenital Melanocytic Nevi

    by Thomas Rouillé, Selim Aractingi, Natacha Kadlub, Sylvie Fraitag, Alexandre How-Kit, Antoine Daunay, Mikael Hivelin, Philippe Moguelet, Arnaud Picard, Romain H. Fontaine, et al.


  • Varying proliferative and clonogenic potential in NRAS‐mutated congenital melanocytic nevi according to size

    by Sarah Guégan, Natacha Kadlub, Arnaud Picard, Thomas Rouillé, Christelle Charbel, Aurore Coulomb‐L'Hermine, Alexandre How‐Kit, Sylvie Fraitag, Selim Aractingi, Romain H. Fontaine

    Congenital melanocytic nevi (CMN) are benign proliferations that may be associated with various consequences depending on their size. They are characterized by a specific molecular signature, namely a post-zygotic somatic NRAS or BRAF mutation. We have recently reported that large CMN (lCMN), which are classically associated with an increased melanoma risk, harbor cell subpopulations with specific clonogenic and tumorigenic potential. We wished to ascertain whether cells displaying similar properties persisted postnatally in medium CMN (mCMN). Eighteen medium M1, nine large and one giant NRAS-mutated CMN were prospectively included in the study. Subpopulations of mCMN cells expressed stem cell/progenitor lineage markers such as Sox10, Nestin, and Oct4, as was the case in lCMN. Nevertheless, conversely to lCMN, mCMN cells with clonogenic properties were rarer. In vitro, approximatively 1 in 1500 cells isolated from fresh mCMN formed colonies that could be passaged. In vivo, mCMN seemed to harbor cells with less proliferative potential than the larger lesions as lCMN biopsies displayed a three-fold expansion compared to mCMN when xenografted in Rag2(-/-) mice. Thus, our data revealed variations in clonogenicity and tumorigenic properties in NRAS-mutated CMN according to size. This article is protected by copyright. All rights reserved.


  • Clonogenic Cell Subpopulations Maintain Congenital Melanocytic Nevi

    by Christelle Charbel, Romain H. Fontaine, Natacha Kadlub, Aurore Coulomb-L’hErmine, Thomas Rouillé, Alexandre How-Kit, Philippe Moguelet, Jorg Tost, Arnaud Picard, Selim Aractingi, et al.


  • NRAS Mutation Is the Sole Recurrent Somatic Mutation in Large Congenital Melanocytic Nevi

    by Christelle Charbel, Romain H. Fontaine, Gabriel G. Malouf, Arnaud Picard, Natacha Kadlub, Nizar El-Murr, Alexandre How-Kit, Xiaoping Su, Aurore Coulomb-L'Hermine, Jorg Tost, et al.


  • Open Access

    Vascular endothelial growth factor receptor 3 directly regulates murine neurogenesis

    by Charles-Félix Calvo, Romain H. Fontaine, Jihane Soueid, Tuomas Tammela, Taija Makinen, Clara Alfaro-Cervello, Fabien Bonnaud, Andres Miguez, Lucile Benhaim, Yunling Xu, et al.

    Neural stem cells (NSCs) are slowly dividing astrocytes that are intimately associated with capillary endothelial cells in the subventricular zone (SVZ) of the brain. Functionally, members of the vascular endothelial growth factor (VEGF) family can stimulate neurogenesis as well as angiogenesis, but it has been unclear whether they act directly via VEGF receptors (VEGFRs) expressed by neural cells, or indirectly via the release of growth factors from angiogenic capillaries. Here, we show that VEGFR-3, a receptor required for lymphangiogenesis, is expressed by NSCs and is directly required for neurogenesis.Vegfr3:YFPreporter mice show VEGFR-3 expression in multipotent NSCs, which are capable of self-renewal and are activated by the VEGFR-3 ligand VEGF-C in vitro. Overexpression of VEGF-C stimulates VEGFR-3-expressing NSCs and neurogenesis in the SVZ without affecting angiogenesis. Conversely, conditional deletion ofVegfr3in neural cells, inducible deletion in subventricular astrocytes, and blocking of VEGFR-3 signaling with antibodies reduce SVZ neurogenesis. Therefore, VEGF-C/VEGFR-3 signaling acts directly on NSCs and regulates adult neurogenesis, opening potential approaches for treatment of neurodegenerative diseases.


  • Nitric Oxide Plays a Key Role in Myelination in the Developing Brain

    by Paul Olivier, Gauthier Loron, Romain H. Fontaine, Julien Pansiot, Jérémie Dalous, Hoa Pham Thi, Christiane Charriaut-Marlangue, Jean-Léon Thomas, Jean-Christophe Mercier, Pierre Gressens, et al.

    Inhaled nitric oxide (iNO) is one of the most promising therapies used in neonates, but there is little information available about its effect on the developing brain. We explored the effects of both iNO and endogenous NO on developing white matter in rodents. Rat or mouse pups and their mothers were placed in a chamber containing 5 to 20 ppm of NO for 7 days after birth. Neonatal exposure to iNO was associated with a transient increase in central nervous system myelination in rats and C57BL/6 mice without any deleterious effects at low doses (5 ppm) or behavioral consequences in adulthood. Exposure to iNO was associated with a proliferative effect on immature oligodendrocytes and a subsequent promaturational effect. The role of endogenous NO in myelination was investigated in animals treated with the nitric oxides synthase inhibitor N (G)-nitro-L-arginine methyl ester (L-NAME) in the neonatal period; this led to protracted myelination defects and subsequent behavioral deficits in adulthood. These effects were reversed by rescuing L-NAME-treated animals with iNO. Thus, we demonstrate considerable effect of both exogenous and endogenous NO on myelination in rodents. These data point to potential new avenues for neuroprotection in human perinatal brain damage.


  • Open Access

    Correction: Melatonin Promotes Oligodendroglial Maturation of Injured White Matter in Neonatal Rats

    by Paul Olivier, Romain H. Fontaine, Gauthier Loron, Juliette Van Steenwinckel, Valérie Biran, Véronique Massonneau, Angela Kaindl, Jeremie Dalous, Christiane Charriaut-Marlangue, Marie-Stéphane Aigrot, et al.


  • Open Access

    Melatonin Promotes Oligodendroglial Maturation of Injured White Matter in Neonatal Rats

    by Paul Olivier, Romain H. Fontaine, Gauthier Loron, Juliette Van Steenwinckel, Valérie Biran, Véronique Massonneau, Angela Kaindl, Jeremie Dalous, Christiane Charriaut-Marlangue, Marie-Stéphane Aigrot, et al.

    To investigate the effects of melatonin treatment in a rat model of white matter damage (WMD) in the developing brain. Additionally, we aim to delineate the cellular mechanisms of melatonin effect on the oligodendroglial cell lineage. A unilateral ligation of the uterine artery in pregnant rat at the embryonic day 17 induces fetal hypoxia and subsequent growth restriction (GR) in neonatal pups. GR and control pups received a daily intra-peritoneal injection of melatonin from birth to post-natal day (P) 3. Melatonin administration was associated with a dramatic decrease in microglial activation and astroglial reaction compared to untreated GR pups. At P14, melatonin prevented white matter myelination defects with an increased number of mature oligodendrocytes (APC-immunoreactive) in treated GR pups. Conversely, melatonin was not found to be associated with an increased density of total oligodendrocytes (Olig2-immunoreactive), suggesting that melatonin is able to promote oligodendrocyte maturation but not proliferation. These effects appear to be melatonin-receptor dependent and were reproduced in vitro. These data suggest that melatonin has a strong protective effect on developing damaged white matter through decreased microglial activation and oligodendroglial maturation leading to a normalization of the myelination process. Consequently, melatonin should be a considered as an effective neuroprotective candidate not only in perinatal brain damage but also in inflammatory and demyelinating diseases observed in adults.


  • Vulnerability of white matter towards antenatal hypoxia is linked to a species-dependent regulation of glutamate receptor subunits

    by Romain H. Fontaine, Paul Olivier, Véronique Massonneau, Philippe Leroux, Vincent Degos, Sophie Lebon, Vincent El Ghouzzi, Vincent Lelièvre, Pierre Gressens, Olivier Baud

    White-matter damage is a leading cause of neurological handicap. Although hypoxia-ischemia and excitotoxicity are major pathogenic factors, a role for genetic influences was suggested recently. Thus, protracted gestational hypoxia was associated with white-matter damage (WMD) in rat pups but not in mouse pups. Indeed, microglial activation and vessel-wall density on postnatal days (P)1 and P10 were found increased in both mouse and rat pups, but cell death, astrogliosis, and myelination were only significantly altered in hypoxic rat pups. We investigated whether this species-related difference was ascribable to effects of antenatal hypoxia on the expression of glutamate receptor subunits by using immunocytochemistry, PCR, and excitotoxic double hit insult. Quantitative PCR in hypoxic mouse pups on P1 showed 2- to 4-fold down-regulation of the AMPA-receptor subunits -1, 2, and -4; of the kainate-receptor subunit GluR7; and of the metabotropic receptor subunits mGluR1, -2, -3, -5, and -7. None of the glutamate-receptor subunits was down-regulated in the hypoxic rat pups. NR2B was the only NMDA-receptor subunit that was down-regulated in hypoxic mice but not in hypoxic rat on P1. Ifenprodil administration to induce functional inhibition of NMDA containing NR2B-subunit receptors prevented hypoxia-induced myelination delay in rat pups. Intracerebral injection of a glutamate agonist produced a larger decrease in ibotenate-induced excitotoxic lesions in hypoxic mouse pups than in normoxic mouse pups. Gestational hypoxia may regulate the expression of specific glutamate-receptor subunits in fetal mice but not in fetal rats. Therefore, genetic factors may influence the susceptibility of rodents to WMD.


  • IL-9/IL-9 receptor signaling selectively protects cortical neurons against developmental apoptosis

    by R H Fontaine, O Cases, V Lelièvre, B Mesplès, J-C Renauld, G Loron, V Degos, P Dournaud, O Baud, P Gressens

    In mammals, programmed cell death (PCD) is a central event during brain development. Trophic factors have been shown to prevent PCD in postmitotic neurons. Similarly, cytokines have neurotrophic effects involving regulation of neuronal survival. Nevertheless, neuronal PCD is only partially understood and host determinants are incompletely defined. The present study provides evidence that the cytokine interleukin-9 (IL-9) and its receptor specifically control PCD of neurons in the murine newborn neocortex. IL-9 antiapoptotic action appeared to be time-restricted to early postnatal stages as both ligand and receptor transcripts were mostly expressed in neocortex between postnatal days 0 and 10. This period corresponds to the physiological peak of apoptosis for postmitotic neurons in mouse neocortex. In vivo studies showed that IL-9/IL-9 receptor pathway inhibits apoptosis in the newborn neocortex. Furthermore, in vitro studies demonstrated that IL-9 and its receptor are mainly expressed in neurons. IL-9 effects were mediated by the activation of the JAK/STAT (janus kinase/signal transducer and activator of transcription) pathway, whereas nuclear factor-κB (NF-κB) or Erk pathways were not involved in mediating IL-9-induced inhibition of cell death. Finally, IL-9 reduced the expression of the mitochondrial pro-apoptotic factor Bax whereas Bcl-2 level was not significantly affected. Together, these data suggest that IL-9/IL-9 receptor signaling pathway represents a novel endogenous antiapoptotic mechanism for cortical neurons by controlling JAK/STAT and Bax levels.